Intech Investment Management LLC Buys Shares of 20,078 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Intech Investment Management LLC bought a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 20,078 shares of the biopharmaceutical company’s stock, valued at approximately $892,000.

Several other hedge funds also recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in Agios Pharmaceuticals by 0.8% in the first quarter. Vanguard Group Inc. now owns 5,572,021 shares of the biopharmaceutical company’s stock worth $162,926,000 after purchasing an additional 44,583 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in shares of Agios Pharmaceuticals by 1.8% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 31,144 shares of the biopharmaceutical company’s stock worth $911,000 after acquiring an additional 540 shares in the last quarter. Tidal Investments LLC bought a new stake in shares of Agios Pharmaceuticals during the 1st quarter worth about $946,000. Harbor Capital Advisors Inc. increased its holdings in shares of Agios Pharmaceuticals by 70.0% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 32,770 shares of the biopharmaceutical company’s stock valued at $1,413,000 after acquiring an additional 13,494 shares during the last quarter. Finally, Northcape Wealth Management LLC bought a new position in shares of Agios Pharmaceuticals in the 2nd quarter valued at approximately $244,000.

Analysts Set New Price Targets

A number of brokerages have issued reports on AGIO. Leerink Partners cut Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. Leerink Partnrs cut shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Finally, Raymond James reiterated an “outperform” rating and issued a $51.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $52.33.

Agios Pharmaceuticals Stock Performance

Shares of AGIO opened at $58.66 on Friday. Agios Pharmaceuticals, Inc. has a 52 week low of $20.96 and a 52 week high of $62.58. The firm has a market capitalization of $3.35 billion, a P/E ratio of 5.16 and a beta of 0.75. The company has a 50-day simple moving average of $48.19 and a 200-day simple moving average of $45.13.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the sale, the chief financial officer now directly owns 20,158 shares in the company, valued at approximately $988,346.74. The trade was a 11.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.